Nature of the Business (Details) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 12, 2024
USD ($)
$ / shares
shares
|
Jul. 18, 2023
shares
|
Jul. 31, 2023
USD ($)
$ / shares
shares
|
Nov. 30, 2022
Item
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
shares
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| Nature of the Business | |||||||||||
| Net proceeds from IPO | $ 450,000 | $ 315,400 | |||||||||
| Accumulated deficit | $ (427,351) | $ (427,351) | $ (305,916) | ||||||||
| Net Income (Loss) | (66,096) | $ (55,339) | $ (33,816) | $ (32,094) | (121,435) | $ (65,910) | |||||
| Negative cash flows from operations | 110,506 | 60,936 | |||||||||
| Cash and cash equivalents | 124,192 | $ 307,299 | 124,192 | $ 307,299 | |||||||
| Marketable securities | 381,228 | 381,228 | 378,864 | ||||||||
| Long-term marketable securities | $ 115,769 | $ 115,769 | $ 210,416 | ||||||||
| IPO | |||||||||||
| Nature of the Business | |||||||||||
| Shares issued | shares | 7,790,321 | 20,297,500 | 20,297,500 | ||||||||
| Share price | $ / shares | $ 62 | $ 17 | |||||||||
| Overallotment option | |||||||||||
| Nature of the Business | |||||||||||
| Shares issued | shares | 1,016,128 | 2,647,500 | 7,790,321 | ||||||||
| Option Agreement | Related party | Paragon Therapeutics, Inc | |||||||||||
| Nature of the Business | |||||||||||
| Number of selected targets initially included under the agreement | Item | 2 | ||||||||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Represents the number of selected targets initially included under agreements. No definition available.
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's first offering of stock to the public net of costs. No definition available.
|
| X | ||||||||||
- Definition Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of investment in marketable security, classified as current. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of investment in marketable security, classified as noncurrent. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of accumulated undistributed earnings (deficit). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|